Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 and D-1553 in KRAS G12C-mutant NSCLC
NCT07174908Phase 3Recruiting
- Sponsor
- InxMed
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ifebemtinib and garsorasib in non-small cell lung cancer (NSCLC), sponsored by InxMed. Primary endpoint: Progression-Free Survival at 36 months. Started Sep 2025; status: recruiting.
02
Drugs
ifebemtinibgarsorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07174908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174908.